Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.
Identifieur interne : 001C56 ( Ncbi/Curation ); précédent : 001C55; suivant : 001C57Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.
Auteurs : B A Faucheux ; N. Nillesse ; P. Damier ; G. Spik ; A. Mouatt-Prigent ; A. Pierce ; B. Leveugle ; N. Kubis ; J J Hauw ; Yves Agid [France]Source :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 1995.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antibody Specificity, Humans, Immunoblotting, Immunohistochemistry, Lactoferrin (metabolism), Microcirculation (chemistry), Microcirculation (cytology), Neuroglia (chemistry), Neuroglia (cytology), Neurons (chemistry), Neurons (cytology), Parkinson Disease, Receptors, Cell Surface (analysis), Receptors, Cell Surface (immunology), Substantia Nigra (blood supply), Substantia Nigra (chemistry), Substantia Nigra (cytology).
- MESH :
- chemical , analysis : Receptors, Cell Surface.
- chemical , immunology : Receptors, Cell Surface.
- chemical , metabolism : Lactoferrin.
- blood supply : Substantia Nigra.
- chemistry : Microcirculation, Neuroglia, Neurons, Substantia Nigra.
- cytology : Microcirculation, Neuroglia, Neurons, Substantia Nigra.
- Aged, Aged, 80 and over, Antibody Specificity, Humans, Immunoblotting, Immunohistochemistry, Parkinson Disease.
Abstract
The degeneration of nigral dopaminergic neurons in Parkinson disease is believed to be associated with oxidative stress. Since iron levels are increased in the substantia nigra of parkinsonian patients and this metal catalyzes the formation of free radicals, it may be involved in the mechanisms of nerve cell death. The cause of nigral iron increase is not understood. Iron acquisition by neurons may occur from iron-transferrin complexes with a direct interaction with specific membrane receptors, but recent results have shown a low density of transferrin receptors in the substantia nigra. To investigate whether neuronal death in Parkinson disease may be associated with changes in a pathway supplementary to that of transferrin, lactoferrin (lactotransferrin) receptor expression was studied in the mesencephalon. In this report we present evidence from immunohistochemical staining of postmortem human brain tissue that lactoferrin receptors are localized on neurons (perikarya, dendrites, axons), cerebral microvasculature, and, in some cases, glial cells. In parkinsonian patients, lactoferrin receptor immunoreactivity on neurons and microvessels was increased and more pronounced in those regions of the mesencephalon where the loss of dopaminergic neurons is severe. Moreover, in the substantia nigra, the intensity of immunoreactivity on neurons and microvessels was higher for patients with higher nigral dopaminergic loss. These data suggest that lactoferrin receptors on vulnerable neurons may increase intraneuronal iron levels and contribute to the degeneration of nigral dopaminergic neurons in Parkinson disease.
Url:
PubMed: 7568181
PubMed Central: 40850
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000309
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000307
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000967
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001613
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001572
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001572
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001C56
Links to Exploration step
PMC:40850Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.</title>
<author><name sortKey="Faucheux, B A" sort="Faucheux, B A" uniqKey="Faucheux B" first="B A" last="Faucheux">B A Faucheux</name>
</author>
<author><name sortKey="Nillesse, N" sort="Nillesse, N" uniqKey="Nillesse N" first="N" last="Nillesse">N. Nillesse</name>
</author>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
</author>
<author><name sortKey="Spik, G" sort="Spik, G" uniqKey="Spik G" first="G" last="Spik">G. Spik</name>
</author>
<author><name sortKey="Mouatt Prigent, A" sort="Mouatt Prigent, A" uniqKey="Mouatt Prigent A" first="A" last="Mouatt-Prigent">A. Mouatt-Prigent</name>
</author>
<author><name sortKey="Pierce, A" sort="Pierce, A" uniqKey="Pierce A" first="A" last="Pierce">A. Pierce</name>
</author>
<author><name sortKey="Leveugle, B" sort="Leveugle, B" uniqKey="Leveugle B" first="B" last="Leveugle">B. Leveugle</name>
</author>
<author><name sortKey="Kubis, N" sort="Kubis, N" uniqKey="Kubis N" first="N" last="Kubis">N. Kubis</name>
</author>
<author><name sortKey="Hauw, J J" sort="Hauw, J J" uniqKey="Hauw J" first="J J" last="Hauw">J J Hauw</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">7568181</idno>
<idno type="pmc">40850</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC40850</idno>
<idno type="RBID">PMC:40850</idno>
<date when="1995">1995</date>
<idno type="wicri:Area/Pmc/Corpus">000309</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000309</idno>
<idno type="wicri:Area/Pmc/Curation">000307</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000307</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000967</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000967</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001613</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001613</idno>
<idno type="wicri:Area/PubMed/Curation">001572</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001572</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001572</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001572</idno>
<idno type="wicri:Area/Ncbi/Merge">001C56</idno>
<idno type="wicri:Area/Ncbi/Curation">001C56</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.</title>
<author><name sortKey="Faucheux, B A" sort="Faucheux, B A" uniqKey="Faucheux B" first="B A" last="Faucheux">B A Faucheux</name>
</author>
<author><name sortKey="Nillesse, N" sort="Nillesse, N" uniqKey="Nillesse N" first="N" last="Nillesse">N. Nillesse</name>
</author>
<author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
</author>
<author><name sortKey="Spik, G" sort="Spik, G" uniqKey="Spik G" first="G" last="Spik">G. Spik</name>
</author>
<author><name sortKey="Mouatt Prigent, A" sort="Mouatt Prigent, A" uniqKey="Mouatt Prigent A" first="A" last="Mouatt-Prigent">A. Mouatt-Prigent</name>
</author>
<author><name sortKey="Pierce, A" sort="Pierce, A" uniqKey="Pierce A" first="A" last="Pierce">A. Pierce</name>
</author>
<author><name sortKey="Leveugle, B" sort="Leveugle, B" uniqKey="Leveugle B" first="B" last="Leveugle">B. Leveugle</name>
</author>
<author><name sortKey="Kubis, N" sort="Kubis, N" uniqKey="Kubis N" first="N" last="Kubis">N. Kubis</name>
</author>
<author><name sortKey="Hauw, J J" sort="Hauw, J J" uniqKey="Hauw J" first="J J" last="Hauw">J J Hauw</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="ISSN">0027-8424</idno>
<idno type="eISSN">1091-6490</idno>
<imprint><date when="1995">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibody Specificity</term>
<term>Humans</term>
<term>Immunoblotting</term>
<term>Immunohistochemistry</term>
<term>Lactoferrin (metabolism)</term>
<term>Microcirculation (chemistry)</term>
<term>Microcirculation (cytology)</term>
<term>Neuroglia (chemistry)</term>
<term>Neuroglia (cytology)</term>
<term>Neurons (chemistry)</term>
<term>Neurons (cytology)</term>
<term>Parkinson Disease</term>
<term>Receptors, Cell Surface (analysis)</term>
<term>Receptors, Cell Surface (immunology)</term>
<term>Substantia Nigra (blood supply)</term>
<term>Substantia Nigra (chemistry)</term>
<term>Substantia Nigra (cytology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Receptors, Cell Surface</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Receptors, Cell Surface</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Lactoferrin</term>
</keywords>
<keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Microcirculation</term>
<term>Neuroglia</term>
<term>Neurons</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Microcirculation</term>
<term>Neuroglia</term>
<term>Neurons</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibody Specificity</term>
<term>Humans</term>
<term>Immunoblotting</term>
<term>Immunohistochemistry</term>
<term>Parkinson Disease</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The degeneration of nigral dopaminergic neurons in Parkinson disease is believed to be associated with oxidative stress. Since iron levels are increased in the substantia nigra of parkinsonian patients and this metal catalyzes the formation of free radicals, it may be involved in the mechanisms of nerve cell death. The cause of nigral iron increase is not understood. Iron acquisition by neurons may occur from iron-transferrin complexes with a direct interaction with specific membrane receptors, but recent results have shown a low density of transferrin receptors in the substantia nigra. To investigate whether neuronal death in Parkinson disease may be associated with changes in a pathway supplementary to that of transferrin, lactoferrin (lactotransferrin) receptor expression was studied in the mesencephalon. In this report we present evidence from immunohistochemical staining of postmortem human brain tissue that lactoferrin receptors are localized on neurons (perikarya, dendrites, axons), cerebral microvasculature, and, in some cases, glial cells. In parkinsonian patients, lactoferrin receptor immunoreactivity on neurons and microvessels was increased and more pronounced in those regions of the mesencephalon where the loss of dopaminergic neurons is severe. Moreover, in the substantia nigra, the intensity of immunoreactivity on neurons and microvessels was higher for patients with higher nigral dopaminergic loss. These data suggest that lactoferrin receptors on vulnerable neurons may increase intraneuronal iron levels and contribute to the degeneration of nigral dopaminergic neurons in Parkinson disease.</p>
<sec sec-type="scanned-figures"><title>Images</title>
<fig id="F1"><label>Fig. 1</label>
<graphic xlink:href="pnas01499-0185-a" xlink:role="9604"></graphic>
</fig>
<fig id="F2"><label>Fig. 2</label>
<graphic xlink:href="pnas01499-0186-a" xlink:role="9605"></graphic>
</fig>
</sec>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001C56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Curation |type= RBID |clé= PMC:40850 |texte= Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:7568181" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |